Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma AG
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information
This expanded treatment protocol (ETP) will provide pediatric/young adult patients with relapsed or refractory B-cell ALL the opportunity to be treated with CTL019 after the closure of the Novartis si...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The primary objective is to assess the safety of the same-day administration of photodynamic therapy with Visudyne® and an intravitreal injection of RFB002 (ranibizumab). Safety of the combined treatm...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety, and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal antibody) with three different dose regimens in patients with active rheumatoid arthritis despite stable treatment with methotrexate
To assess the efficacy of three dose regimens of ACZ885 ( (1) 600 mg i.v. loading dose plus 300 mg s.c. q2wk, (2) 300 mg s.c. q2wk, (3) 150 mg s.c. q4wk) compared to placebo as add-on treatment in pat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A 24-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
1. The main purpose of this amendment is to extend the study duration. Based upon feedback from Health Authorities in France, Sweden and USA the study is extended to allow collection of long term (2 y...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension
• To evaluate the long-term safety and tolerability of QTI571
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG (UK)
MAJ Il y a 5 ans
Study of preoperative everolimus in metastatic renal cell cancer
http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-using-everolimus-advanced-kidney-cancer
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors
Phase Ib: Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) by measuring incidence of dose limiting toxicities Phase II: Antitumor activity of MEK162 in combina...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload
•Participants With Adverse Events by Primary System Organ Class (SOC) [ Time Frame: 4 year extension + core 1 year ] Safety parameters were measured by the number and type of adverse events (AEs). A...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)
- To determine the safety and tolerability of LMB763 during 12 weeks of treatment - To determine the effect of LMB763 on circulating alanine aminotransferase (ALT) levels
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Efficacy and Safety of the paediatric formulation (dispersible tablet) of Coartem® in Children (weighing 5 kg to less than 35 kg ) with uncomplicated Plasmodium falciparum malaria
To confirm the efficacy of the Coartem pediatric formulation in infants and children with a body weight of ≥5 kg and <35 kg suffering from P. falciparum malaria by testing the hypothesis that Coartem ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant